Functionalized diterpene parvifloron D-loaded hybrid nanoparticles for targeted delivery in melanoma therapy

Author:

Silva Catarina Oliveira12,Molpeceres Jesús2,Batanero Belén3,Fernandes Ana Sofia14,Saraiva Nuno1,Costa João Guilherme14,Rijo Patrícia14,Figueiredo Isabel Vitória56,Faísca Pedro7,Reis Catarina Pinto18

Affiliation:

1. CBiOS, Research Center for Biosciences & Health Technologies, Universidade Lusófona, Campo Grande 376, 1749–024 Lisboa, Portugal

2. Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá, Spain

3. Department of Organic & Inorganic Chemistry, Faculty of Pharmacy, University of Alcalá, Spain

4. Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal

5. Pharmacology & Pharmaceutical Care, Faculty of Pharmacy, Universidade de Coimbra, Portugal

6. IBILI, Institute for Biomedical Imaging & Life Sciences, Universidade de Coimbra, Portugal

7. Faculty of Veterinary Medicine – Universidade Lusófona, Lisboa, Portugal

8. IBEB, Biophysics & Biomedical Engineering, Faculty of Sciences, Universidade de Lisboa, Portugal

Abstract

Aim: Parvifloron D is a natural diterpene with a broad and not selective cytotoxicity toward human tumor cells. In order to develop a targeted antimelanoma drug delivery platform for Parvifloron D, hybrid nanoparticles were prepared with biopolymers and functionalized with α-melanocyte stimulating hormone. Results/methodology: Nanoparticles were produced according to a solvent displacement method and the physicochemical properties were assessed. It was shown that Parvifloron D is cytotoxic and can induce, both as free and as encapsulated drug, cell death in melanoma cells (human A375 and mouse B16V5). Parvifloron D-loaded nanoparticles showed a high encapsulation efficiency (87%) and a sustained release profile. In vitro experiments showed the nanoparticles’ uptake and cell internalization. Conclusion: Hybrid nanoparticles appear to be a promising platform for long-term drug release, presenting the desired structure and a robust performance for targeted anticancer therapy.

Publisher

Future Science Ltd

Subject

Pharmaceutical Science

Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3